• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Compass Pathways Takes Investors on a Trip to Higher Prices

Fresh off IPO, company sees mushrooming opportunity in psilocybin.
By DEBRA BORCHARDT
Sep 22, 2020 | 11:00 AM EDT
Stocks quotes in this article: CMPS, TLRY

Psychedelic company Compass Pathways PLC (CMPS)  got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares.

The U.K.-based mental health care company said on Friday that it had upped its initial public offering, and priced the shares at $17, which was higher than the expected range of $14 to $16 a share. The first trade was at 37.6% above the initial public offering price sending the stock to roughly $23. The stock was continuing to move higher and was lately selling at $29.

Initially the company was valued at $578 million, but the market cap eventually hit a billion. According to its prospectus, Compass reported total net losses of $13.2 million, $19.6 million and $24.8 million, respectively, for the fiscal years ended Dec. 31, 2018 and Dec. 31, 2019 and the six months ended June 30. Perhaps at some point investors will right size the market cap.

Compass had raised $116 million prior to its IPO. As of June 30, it had an accumulated deficit of $62.4 million. Its largest shareholder is Atai Life Sciences, which owns 29% of the stock. Other large shareholders include founders, George Goldsmith and Ekaterina Malievskaia, each with 16.5% of the company. Entities affiliated with Peter Thiel own 7.5%.

Psychedelic company stock traders will need to be extra cautious as this category has become very volatile with the rush to get into the early stages of the industry. Investors may recall that in 2018 when Tilray (TLRY)  went public, the stock trading had to be halted five times and shares briefly hit $300. Tilray shares now trade at $5.

Psilocybin Treatments for Depression

The company is known for its development of a new model of psilocybin therapy, in which psilocybin, a compound derived from a type of mushroom, is administered in conjunction with psychological support. This is not unlike the ketamine clinics, in which patients will take ketamine treatment under the guidance of a mental health professional.

"Our initial focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the current treatment paradigm," says the company in its overview. The company noted in its filing that early signals from academic studies, using formulations of psilocybin of other sources, have shown that psilocybin therapy "may have the potential to improve outcomes for patients suffering with depression, with rapid reductions in depression symptoms and effects lasting up to six months, after administration of a single high dose."

The company has targeted the depression market, which is seen as valued at $200 billion.

It also says that it has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, that it's calling COMP360. In 2019, it completed its first phase clinical trial, administering COMP360, along with psychological support, to 89 healthy volunteers, the largest randomized controlled clinical trial with psilocybin therapy to date, according to Compass Pathways. It found it was generally well-tolerated and is currently evaluating COMP360 in conjunction with psychological support in another trial.

That Phase IIb clinical trial consists of 216 patients suffering with TRD, in 20 sites across North America and Europe. This trial is investigating the safety and efficacy of COMP360 combined with psychological support, for the treatment of TRD, and aims to determine the optimal dose of COMP360. The trial is expected to yield results in late 2021.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no position in any of the stocks mentioned in this story.

TAGS: IPOs | Investing | Stocks | Biotechnology | Pharmaceuticals | Europe | Cannabis

More from Stocks

The Markets Also Rise Quickly

James "Rev Shark" DePorre
Mar 1, 2021 4:22 PM EST

Fear of missing out permeated the day as the indexes bounced back.

BlackBerry's Calling

Mark Sebastian
Mar 1, 2021 3:27 PM EST

Here's a play in the stock and why I think it will dial back down.

NantKwest's Charts Are Extended When Compared to the Popular Moving Averages

Bruce Kamich
Mar 1, 2021 3:15 PM EST

Let's stand aside for now and see how things unfold.

The Battle Over Cannabis Operator Verano Holdings' Stock

Debra Borchardt
Mar 1, 2021 2:00 PM EST

Sol Global and MMCap are fighting in court over who owns or owes what of the company's shares.

Is Chevron Finally Ready to Make an Upside Breakout?

Bruce Kamich
Mar 1, 2021 1:44 PM EST

Let's check out some charts on the energy giant.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) up on take-over rumors

    The NYT says talks are underway regarding a buyo...
  • 08:09 AM EST GARY BERMAN

    Monday Morning Fibocall for 3/1/2021

    Always a good idea to know where our bounce zones ...
  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login